Jesse Qiao

Dr. Jesse Qiao

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
JQJesse Qiao
Jesse Qiao
MTMinh-Ha Tran
Minh-Ha Tran
Direct oral anticoagulants (DOACs) exert anticoagulation effect by directly inhibiting Factor Xa (rivaroxaban, apixaban, and edoxaban) or thrombin (dabigatran). Though DOACs are characterized by fixed-dose prescribing and generally do not require routine laboratory drug-level monitoring (DLM), circumstances may arise where the DLM may aid in clinical decision-making, including DOAC dose adjustment, anticoagulant class change, or decisions to withhold or administer reversal agents. We review the current literature that describes high-risk patient groups in which DLM may be beneficial for improved patient anticoagulation management and stewardship. The review also summarizes the limitations of conventional coagulation testing and discuss the emerging utility of quantitative methods for routine and rapid emergent evaluation of DOAC drug levels—in particular, the Anti-Xa activity to detect Factor Xa Inhibitors (rivaroxaban, apixaban, and edoxaban). Both technical and regulatory barriers to widespread DLM implementation are limiting factors to further clinical research that must be overcome, in order to propose universal DOAC DLM strategies and provide clinical-laboratory correlation to formally classify high-risk patient groups.

1 January 2024 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
JQJesse Qiao
Jesse Qiao
JBJenique Bailly
Jenique Bailly
JOJessica Opie
Jessica Opie
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by antiphospholipid antibodies associated with thrombosis and pregnancy complications. Catastrophic APS is a severe form involving multiple organ systems with a high mortality rate. The pathogenesis involves antiphospholipid antibodies which target phospholipid-binding proteins and damage endothelial cells thus activating coagulation, triggering a pro-thrombotic state. Laboratory tests for antiphospholipid antibody detection include lupus anticoagulant testing in the coagulation laboratory and serological detection of anticardiolipin and anti-beta 2 glycoprotein I antibodies. Despite recent updates in the diagnostic criteria for APS the recent decades and our improved knowledge of this disease, there remain several key issues pertaining to diagnosis and testing with potential implications to patient management. Here we briefly review APS pathophysiology, strengths and weaknesses of classification criteria, laboratory challenges leading to test interpretation, and clinical management of this complex condition.

23 September 2021 in Vox Sanguinis
Verified
Journal Article
Open access
PDF file
JQJesse Qiao
Jesse Qiao
BRBradford Ray
Bradford Ray
FWFrank Wians
Frank Wians
JAJude Abadie
Jude Abadie
Background and Objectives Mortality rates, transfusion ratios, trauma management logistics, and assault characteristics from the El Paso mass shooting incident (MSI) are evaluated in comparison to other MSIs. In 2019, El Paso, TX experienced the eighth-deadliest MSIs in modern US history. In this 21st mass killing in the United States of 2019, 19 people died immediately, and four of 27 injured, later died from ballistic injuries. Materials and Methods We examined the victims' injuries, pre-hospital treatments, transfusions, rotational thromboelastometry (ROTEM) interpretation, tranexamic acid (TXA) use, and compared El Paso's outcomes with other MSIs. Results Fifteen casualties were treated for bullet injuries at University Medical Center (UMC). Three were in critical condition; one died during surgery. Of the remaining victims, two were guarded, and the remaining ten in stable condition. Anatomic trauma locations included chest, abdomen, hip, breast, thigh and arm. Haemostatic agents and TXA were administered to arriving patients. Seven casualties receiving blood products were administered 95 units at UMC (45 red blood cells [RBC], 38 fresh frozen plasma [FFP], 8 platelets and 4 cryoprecipitate). ROTEM guided mass transfusion decisions in three patients. Out of seven MSIs reviewed, El Paso had the highest mortality rate (50.0%) and lowest RBC:FFP:admission ratio (1.18 at UMC). Conclusion We report the greatest proportion of transfusions per admission for an MSI and are first to discuss ROTEM roles to guide transfusion and manage coagulopathy during an MSI. This case highlights the severity and impact of MSIs on victims and requirements to follow established transfusion protocols with adjunct use of ROTEM, TXA and haemostatic agents.

7 June 2025 in Transfusion and Apheresis Science
Verified
Journal Article
Open access
MTMinh-Ha Tran
Minh-Ha Tran
JJJennifer Jones
Jennifer Jones
JQJesse Qiao
Jesse Qiao
Immune Thrombotic thrombocytopenic purpura (iTTP) is a rare but life-threatening thrombotic microangiopathy characterized by an autoantibody against ADAMTS13, leading to accumulation of ultra-large von Willebrand multimers, systemic platelet microthrombi, end-organ damage, and mortality if untreated. Therapeutic plasma exchange and corticosteroids have been the mainstay therapy for decades, but there exists significant relapse potential after the initial acute episode. While more recent advances in the use of immunotherapy (e.g. rituximab and caplacizumab) have significantly improved acute survival and short-term exacerbation/relapse prevention, long-term complications of the disease remain a concern for survivors. This narrative review discusses challenges of optimizing post-remission care after iTTP, highlighting disease impact on neurological, cardiovascular, and psychological health. Chronic cognitive impairment, increased risk of hypertension and ischemic events, and mental health challenges such as anxiety and depression are reported in iTTP survivors. Moreover, recurrence risk and persistent ADAMTS13 deficiency may define the need for long-term monitoring and individualized treatment of potential relapse. We emphasize the importance of multidisciplinary, patient-centered management, not only in the management and prevention of iTTP relapse episodes, but to improve quality of life and reduce morbidity in survivors of this rare disease. Providers should possess heightened awareness of long-term complications and atypical manifestations of relapse in survivors. We advocate for further research and observational cohort studies to formulate standardized guidelines for surveillance and intervention to mitigate the chronic burden of iTTP.

1 September 2017 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
ASAdam L. Booth, MD1; Diana Rodgers, MD2; Phillip Osehobo, MD, PhD2; Lalarukh K. Aftab, MD3; Mahmoud A. Eltorky, MD2; Heather L. Stevenson, MD, PhD11Department of Pathology, University of Texas Medical Branch, Galveston2Department of Pathology, WellStar Spa
Adam L. Booth, MD1; Diana Rodgers, MD2; Phillip Osehobo, MD, PhD2; Lalarukh K. Aftab, MD3; Mahmoud A. Eltorky, MD2; Heather L. Stevenson, MD, PhD11Department of Pathology, University of Texas Medical Branch, Galveston2Department of Pathology, WellStar Spa
ABAdam L. Booth
Adam L. Booth
DRDiana Rodgers
Diana Rodgers
POPhillip Osehobo
Phillip Osehobo
LALalarukh K. Aftab
Lalarukh K. Aftab
YSYing Liu, MD, PhD; Lynne Opitz, MD; Guo-Xia Tong, MD, PhDDepartment of Pathology and Laboratory Medicine, Staten Island University Hospital, Sta
Ying Liu, MD, PhD; Lynne Opitz, MD; Guo-Xia Tong, MD, PhDDepartment of Pathology and Laboratory Medicine, Staten Island University Hospital, Sta
Article Citation: (2017) Abstracts and Case Studies From the College of American Pathologists 2017 Annual Meeting (CAP17). Archives of Pathology & Laboratory Medicine: September 2017, Vol. 141, No. 9, pp. e2-e191. https://doi.org/10.5858/arpa.2017-0238-AB
1

4 December 2020 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
HJHeather Jones
Heather Jones
JQJesse Qiao
Jesse Qiao
OPOsvaldo Padilla
Osvaldo Padilla
AOAttilio Orazi
Attilio Orazi
Although primary pancreatic lymphoma is a rare cause of pancreatic mass, this diagnosis should be considered during work‐up. Furthermore, when adequate diagnostic material is available from biopsy, complete workup of the lymphoma, including not only type but also subtype when applicable, should be performed.